Table 2.
Assessment of synergistic effect between 224Ra-CaCO3-MP-2 and carboplatin-paclitaxel or carboplatin-PLD.
| 224 Ra-CaCO 3 -MP-2 (5 mg, 27 kBq) with carboplatin (60 mg/kg)-paclitaxel (10 mg/kg) | |||
|---|---|---|---|
| Treatment | Hazard ratio | 95% CI | p-value |
| Carboplatin-paclitaxel | 0.0823 | (0.0251–0.2691) | < 0.001 |
| 224Ra-CaCO3-MP-2 | 0.9125 | (0.3617–2.3020) | 0.846 |
| Carboplatin-paclitaxel and 224Ra- CaCO3-MP-2 | 0.6020 | (0.1609–2.2523) | 0.451 |
| HRcombination | 0.0452 | na | na |
| HRadditive | 0.0751 | na | na |
| 224 Ra-CaCO 3 -MP-2 (5 mg, 34 kBq) with carboplatin (60 mg/kg)-paclitaxel (10 mg/kg) | |||
| Carboplatin-paclitaxel | 0.0645 | (0.0200–0.2080) | < 0.001 |
| 224Ra-CaCO3-MP-2 | 0.6153 | (0.2444–1.5493) | 0.303 |
| Carboplatin-paclitaxel and 224Ra- CaCO3-MP-2 | 0.8600 | (0.2339–3.1623) | 0.820 |
| HRcombination | 0.0341 | na | na |
| HRadditive | 0.0397 | na | na |
| 224 Ra-CaCO 3 -MP-2 (5 mg, 39 kBq) with carboplatin (60 mg/kg)-paclitaxel (10 mg/kg) | |||
| Carboplatin-paclitaxel | 0.1117 | (0.0399–0.3132) | < 0.001 |
| 224Ra-CaCO3-MP-2 | 1.0801 | (0.4141–2.8174) | 0.875 |
| Carboplatin-paclitaxel and 224Ra- CaCO3-MP-2 | 0.5525 | (0.1404–2.1745) | 0.396 |
| HRcombination | 0.0667 | na | na |
| HRadditive | 0.1206 | na | na |
| 224 Ra-CaCO 3 -MP-2 (5 mg, 22 kBq) with carboplatin (80 mg/kg) -PLD (1.6 mg/kg) | |||
| Carboplatin-PLD | 0.2421 | (0.0944–0.6208) | 0.0032 |
| 224Ra-CaCO3-MP-2 | 0.5262 | (0.2086–1.3273) | 0.1738 |
| Carboplatin-PLD and 224Ra- CaCO3-MP-2 | 0.5023 | (0.1221–2.0658) | 0.3399 |
| HRcombination | 0.0640 | na | na |
| HRadditive | 0.1274 | na | na |
PLD, pegylated liposomal doxorubicin; CI, confidence interval; na, not applicable.